004720 — PharmGen Science Share Price
Last trade - 00:00- KR₩74bn
- KR₩75bn
- KR₩171bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.3 | ||
| Price to Tang. Book | 0.31 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.43 | ||
| EV to EBITDA | 6.65 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 2.25% | ||
| Return on Equity | 1.17% | ||
| Operating Margin | 3.91% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 96,614.31 | 109,866.07 | 150,930.72 | 166,778.83 | 171,286.61 | n/a | n/a | 12.48% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +258.82 | +82.75 | -90.78 | -18.75 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
PharmGen Science Inc, formerly Wooridul Pharmaceutical Ltd, is a Korea-based company principally engaged in the manufacturing and distribution of pharmaceuticals. The Company’s products include antiepileptic agents, anti-inflammatory agents, antiphlogistic agents, central nervous system agents, urinary agents, antihistamine agents, antivirus agents, agents for bones, agents for livers, calcium agents, antibiotics, diabetes agents, respiratory agents, as well as over-the-counter (OTC) drugs, obesity drugs, health food and others. In addition, the Company is also engaged in the manufacturing, wholesale and retail distribution of functional cosmetics. The Company distributes its products within domestic market and to overseas markets.
Directors
- Nam Hyeon Ryu CEO (47)
- Hye Yeon Kim OTH (56)
- Yun Ju Lee OTH (46)
- Jae Man Yoo OTH (58)
- Ui Sang Han DRC (52)
- Geun Hyeong Lee DRC (49)
- Seung Yeol Lee DRC (33)
- Seong Hoe Gu NID (47)
- Eun Chae Jung NID (38)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 22nd, 1966
- Public Since
- June 15th, 1990
- No. of Shareholders
- 21,113
- No. of Employees
- 222
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KSE
- Shares in Issue
- 18,159,394
- Address
- 50, Jeyakgongdan 2-gil, Hyangnam-eup, HWASEONG, 18622
- Web
- http://www.pharmgenscience.com/
- Phone
- +82 221943532
- Auditors
- TAEYUL ACCOUNTING CORPORATION
Upcoming Events for 004720
Similar to 004720
Aprogen Biologics
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm Co
Korea Exchange - KSE
Chong Kun Dang Pharmaceutical
Korea Exchange - KSE
CKD Bio
Korea Exchange - KSE
FAQ
As of Today at 22:38 UTC, shares in PharmGen Science are trading at KR₩4,080. This share price information is delayed by 15 minutes.
Shares in PharmGen Science last closed at KR₩4,080 and the price had moved by -22.21% over the past 365 days. In terms of relative price strength the PharmGen Science share price has underperformed the FTSE Developed Asia Pacific Index by -21.32% over the past year.
There is no consensus recommendation for this security.
Find out morePharmGen Science does not currently pay a dividend.
PharmGen Science does not currently pay a dividend.
PharmGen Science does not currently pay a dividend.
To buy shares in PharmGen Science you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩4,080, shares in PharmGen Science had a market capitalisation of KR₩74bn.
Here are the trading details for PharmGen Science:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 004720
Based on an overall assessment of its quality, value and momentum PharmGen Science is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like PharmGen Science. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -7.43%.
As of the last closing price of KR₩4,080, shares in PharmGen Science were trading -12.29% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The PharmGen Science PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩4,080.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
PharmGen Science's management team is headed by:
- Nam Hyeon Ryu - CEO
- Hye Yeon Kim - OTH
- Yun Ju Lee - OTH
- Jae Man Yoo - OTH
- Ui Sang Han - DRC
- Geun Hyeong Lee - DRC
- Seung Yeol Lee - DRC
- Seong Hoe Gu - NID
- Eun Chae Jung - NID